| Literature DB >> 21600013 |
Lisa G Gallagher1, Veronica M Vieira, David Ozonoff, Thomas F Webster, Ann Aschengrau.
Abstract
BACKGROUND: Tetrachloroethylene (PCE) is an important occupational chemical used in metal degreasing and drycleaning and a prevalent drinking water contaminant. Exposure often occurs with other chemicals but it occurred alone in a pattern that reduced the likelihood of confounding in a unique scenario on Cape Cod, Massachusetts. We previously found a small to moderate increased risk of breast cancer among women with the highest exposures using a simple exposure model. We have taken advantage of technical improvements in publically available software to incorporate a more sophisticated determination of water flow and direction to see if previous results were robust to more accurate exposure assessment.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21600013 PMCID: PMC3125233 DOI: 10.1186/1476-069X-10-47
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
PCE exposure history of breast cancer cases and controls
| PCE-exposed cases | PCE-exposed controls | |||
|---|---|---|---|---|
| Latency period (years) | Prior analysis | Current analysis | Prior analysis | Current Analysis |
| (n = 930) | (n = 920) | (n = 1302) | (n = 1293) | |
| 0 | 191 (20.5%) | 449 (48.8%) | 217 (16.7%) | 648 (50.1%) |
| 5 | 154 (16.6%) | 399 (43.4%) | 163 (12.5%) | 552 (42.7%) |
| 7 | 128 (13.8%) | 365 (39.7%) | 135 (10.4%) | 496 (38.4%) |
| 9 | 111 (11.9%) | 319 (34.7%) | 110 (8.4%) | 436 (33.7%) |
| 11 | 86 (9.2%) | 281 (30.5%) | 83 (6.4%) | 376 (29.1%) |
| 13 | 65 (7.0%) | 242 (26.3%) | 52 (4.0%) | 325 (25.1%) |
| 15 | 44 (4.7%) | 186 (20.2%) | 35 (2.7%) | 229 (17.7%) |
| 17 | 21 (2.3%) | 130 (14.1%) | 21 (1.6%) | 141 (10.9%) |
| 19 | 9 (1.0%) | 84 (9.1%) | 9 (0.7%) | 78 (6.0%) |
Distribution of cumulative RDDs among PCE-exposed controls according to latency period
| 75th | |||||
|---|---|---|---|---|---|
| Latency | Minimum | Maximum | Median | Percentile | Percentile |
| 0 | 0.001 | 243.8 | 3.6 | 15.5 | 41.8 |
| 5 | 0.02 | 243.2 | 6.9 | 17.6 | 41.7 |
| 7 | 0.05 | 242.1 | 6.9 | 18.2 | 40.9 |
| 9 | 0.03 | 239.4 | 6.4 | 16.5 | 38.4 |
| 11 | 0.1 | 233.0 | 6.8 | 18.5 | 37.3 |
| 13 | 0.1 | 217.5 | 10.3 | 18.9 | 36.8 |
| 15 | 0.6 | 200.6 | 10.3 | 18.3 | 49.1 |
| 17 | 1.3 | 191.6 | 8.2 | 21.5 | 40.6 |
| 19 | 2.6 | 169.6 | 13.6 | 19.8 | 169.9 |
| 0 | 3.1E-06 | 240.6 | 2.0 | 7.1 | 19.5 |
| 5 | 0.0002 | 240.2 | 2.1 | 8.8 | 20.6 |
| 7 | 0.0004 | 239.4 | 2.4 | 8.0 | 19.0 |
| 9 | 0.0005 | 237.5 | 2.3 | 7.5 | 17.4 |
| 11 | 0.0002 | 232.9 | 1.9 | 6.7 | 16.1 |
| 13 | 0.0002 | 222.0 | 1.4 | 4.9 | 12.8 |
| 15 | 0.0002 | 197.6 | 1.1 | 4.6 | 14.0 |
| 17 | 0.0002 | 140.0 | 1.0 | 3.9 | 11.4 |
| 19 | 0.0004 | 73.4 | 0.6 | 2.1 | 9.5 |
Comparison of percentile categories of PCE exposure by assessment method, no latency
| Automated Method, Current Analysis | |||||||
|---|---|---|---|---|---|---|---|
| N | Unexposed | TOTAL | |||||
| 1095 | 410 | 185 | 92 | 28 | 1810 | ||
| - | |||||||
| 12 | 123 | 42 | 14 | 6 | 197 | ||
| - | |||||||
| 3 | 13 | 28 | 31 | 18 | 93 | ||
| - | |||||||
| 3 | 0 | 7 | 24 | 40 | 74 | ||
| - | |||||||
| 3 | 2 | 2 | 4 | 28 | 39 | ||
| - | |||||||
| 1116 | 548 | 264 | 165 | 120 | 2213 | ||
Note: Mutually exclusive categories shown here, but categories are overlapping (nested) in breast cancer risk analysis. Prior analysis had an RDD value of 3.6, 15.5, and 41.8 for the 50th, 75th and 90th percentiles. Current analysis had an RDD value of 2.0, 7.1, and 19.5 for the 50th, 75th and 90th percentiles. There are 19 subjects that are excluded because current exposure value could not be calculated due to missing data.
Association between breast cancer and any exposure to PCE (ever/never)
| Latency period (years) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|
| 0 | 1.3 (1.0-1.6) | 1.1 (0.9-1.4) |
| 5 | 1.4 (1.1-1.8) | 1.2 (0.9-1.5) |
| 7 | 1.4 (1.1-1.8) | 1.1 (0.8-1.5) |
| 9 | 1.5 (1.1-2.0) | 1.2 (0.9-1.6) |
| 11 | 1.5 (1.1-2.1) | 1.1 (0.8-1.6) |
| 13 | 1.8 (1.3-2.7) | 1.3 (0.9-2.0) |
| 15 | 1.8 (1.2-2.9) | 1.3 (0.8-2.1) |
| 17 | 1.5 (0.8-2.7) | 1.0 (0.5-1.9) |
| 19 | 1.5 (0.6-3.7) | 1.1 (0.4-2.9) |
| 0 | 1.0 (0.8-1.1) | 1.0 (0.8-1.2) |
| 5 | 1.0 (0.8-1.2) | 1.0 (0.8-1.2) |
| 7 | 1.0 (0.9-1.2) | 1.0 (0.9-1.3) |
| 9 | 1.0 (0.8-1.2) | 1.0 (0.8-1.2) |
| 11 | 1.0 (0.9-1.3) | 1.0 (0.8-1.2) |
| 13 | 1.0 (0.8-1.3) | 1.0 (0.8-1.2) |
| 15 | 1.1 (0.9-1.4) | 1.0 (0.8-1.2) |
| 17 | 1.3 (1.0-1.6) | 1.0 (0.7-1.3) |
| 19 | 1.4 (0.9-2.1) | 1.0 (0.7-1.4) |
Note: Referent group in the prior analysis was comprised of never exposed cases (n = 739) and controls (n = 1,085). The referent group in the current analysis was comprised of never exposed cases (n = 471) and controls (n = 645). Both adjusted analyses controlled for age at diagnosis or index year, vital status at interview, family history of breast cancer, personal history of breast cancer (before current diagnosis or index year), age at first live birth or stillbirth, occupational exposure to PCE, and study of origin.
Association between breast cancer and various cumulative PCE exposure
| PCE EXPOSURE LEVEL | ||||
|---|---|---|---|---|
| Latency period (years) | ≤Median | >Median | >75th Percentile | >90th Percentile |
| 0 | ||||
| Case/control | 91/109 | 100/108 | 59/54 | 18/21 |
| COR (95% CI) | 1.2 (0.9-1.6) | 1.4 (1.0-1.8) | 1.6 (1.1-2.3) | 1.3 (0.7-2.4) |
| AOR (95% CI) | 1.0 (0.7-1.3) | 1.2 (0.9-1.7) | 1.6 (1.1-2.4) | 1.3 (0.7-2.6) |
| 5 | ||||
| Case/control | 79/82 | 75/81 | 50/40 | 17/16 |
| COR (95% CI) | 1.4 (1.0-2.0) | 1.4 (1.0-1.9) | 1.8 (1.2-2.8) | 1.6 (0.8-3.1) |
| AOR (95% CI) | 1.1 (0.8-1.5) | 1.3 (0.9-1.8) | 1.6 (1.0-2.6) | 1.5 (0.7-3.0) |
| 7 | ||||
| Case/control | 59/68 | 69/67 | 46/33 | 17/13 |
| COR (95% CI) | 1.3 (0.9-1.8) | 1.5 (1.1-2.1) | 2.0 (1.3-3.2) | 1.9 (0.9-4.0) |
| AOR (95% CI) | 0.9 (0.6-1.3) | 1.3 (0.9-1.9) | 1.8 (1.1-2.9) | 1.7 (0.8-3.6) |
| 9 | ||||
| Case/control | 48/55 | 63/55 | 40/27 | 16/11 |
| COR (95% CI) | 1.3 (0.9-1.9) | 1.7 (1.2-2.4) | 2.2 (1.3-3.6) | 2.1 (1.0-4.6) |
| AOR (95% CI) | 0.9 (0.6-1.4) | 1.4 (0.9-2.0) | 1.9 (1.1-3.2) | 1.9 (0.8-4.4) |
| 11 | ||||
| Case/control | 39/42 | 47/41 | 29/20 | 12/8 |
| COR (95% CI) | 1.4 (0.9-2.1) | 1.7 (1.1-2.6) | 2.1 (1.2-3.8) | 2.2 (0.9-5.4) |
| AOR (95% CI) | 1.0 (0.6-1.5) | 1.4 (0.9-2.1) | 1.8 (1.0-3.3) | 1.8 (0.7-4.8) |
| 13 | ||||
| Case/control | 35/26 | 30/26 | 17/13 | 8/5 |
| COR (95% CI) | 2.0 (1.2-3.3) | 1.7 (1.0-2.9) | 1.9 (0.9-4.0) | 2.3 (0.8-7.2) |
| AOR (95% CI) | 1.4 (0.8-2.3) | 1.3 (0.8-2.3) | 1.6 (0.7-3.5) | 1.7 (0.5-5.2) |
| 15 | ||||
| Case/control | 26/18 | 18/17 | 12/8 | 2/3 |
| COR (95% CI) | 2.1 (1.2-3.9) | 1.6 (0.8-3.0) | 2.2 (0.9-5.4) | 1.0 (0.2-5.9) |
| AOR (95% CI) | 1.5 (0.8-2.8) | 1.1 (0.6-2.3) | 1.7 (0.7-4.3) | - |
| 17 | ||||
| Case/control | 11/11 | 10/10 | 4/5 | 1/2 |
| COR (95% CI) | 1.5 (0.6-3.4) | 1.5 (0.6-3.5) | 1.2 (0.3-4.4) | 0.7 (0.1-8.1) |
| AOR (95% CI) | 1.0 (0.4-2.4) | 1.0 (0.4-2.6) | 0.9 (0.2-3.4) | - |
| 19 | ||||
| Case/control | 6/5 | 3/4 | 2/2 | 0/0 |
| COR (95% CI) | 1.8 (0.5-5.8) | 1.1 (0.2-4.9) | 1.5 (0.2-10.4) | - |
| AOR (95% CI) | 1.3 (0.4-4.2) | 0.9 (0.2-4.1) | - | - |
| 0 | ||||
| Case/control | 224/324 | 225/324 | 123/162 | 56/64 |
| COR (95% CI) | 1.0 (0.8-1.2) | 1.0 (0.8-1.2) | 1.1 (0.8-1.4) | 1.2 (0.8-1.8) |
| AOR (95% CI) | 0.9 (0.8-1.2) | 1.0 (0.8-1.3) | 1.1 (0.9-1.5) | 1.3 (0.9-1.9) |
| 5 | ||||
| Case/control | 193/276 | 206/276 | 104/138 | 53/55 |
| COR (95% CI) | 1.0 (0.8-1.2) | 1.0 (0.8-1.3) | 1.0 (0.8-1.4) | 1.3 (0.9-2.0) |
| AOR (95% CI) | 0.9 (0.7-1.2) | 1.1 (0.9-1.4) | 1.1 (0.8-1.5) | 1.4 (0.9-2.1) |
| 7 | ||||
| Case/control | 176/248 | 189/248 | 101/124 | 51/49 |
| COR (95% CI) | 1.0 (0.8-1.3) | 1.0 (0.8-1.3) | 1.1 (0.8-1.5) | 1.5 (1.0-2.2) |
| AOR (95% CI) | 1.0 (0.8-1.3) | 1.1 (0.9-1.4) | 1.1 (0.8-1.5) | 1.4 (0.9-2.2) |
| 9 | ||||
| Case/control | 148/218 | 171/218 | 89/109 | 47/43 |
| COR (95% CI) | 1.0 (0.7-1.2) | 1.1 (0.9-1.4) | 1.1 (0.8-1.5) | 1.5 (1.0-2.4) |
| AOR (95% CI) | 1.0 (0.7-1.2) | 1.1 (0.8-1.3) | 1.1 (0.8-1.5) | 1.4 (0.9-2.2) |
| 11 | ||||
| Case/control | 122/188 | 159/188 | 75/94 | 40/37 |
| COR (95% CI) | 0.9 (0.7-1.2) | 1.2 (0.9-1.5) | 1.1 (0.8-1.5) | 1.5 (1.0-2.5) |
| AOR (95% CI) | 0.9 (0.7-1.2) | 1.1 (0.8-1.4) | 1.0 (0.7-1.4) | 1.4 (0.9-2.4) |
| 13 | ||||
| Case/control | 106/163 | 136/162 | 73/81 | 37/32 |
| COR (95% CI) | 0.9 (0.7-1.2) | 1.2 (0.9-1.5) | 1.2 (0.9-1.7) | 1.7 (1.0-2.7) |
| AOR (95% CI) | 0.9 (0.7-1.2) | 1.0 (0.8-1.4) | 1.1 (0.8-1.6) | 1.5 (0.9-2.5) |
| 15 | ||||
| Case/control | 85/115 | 101/114 | 50/57 | 20/22 |
| COR (95% CI) | 1.0 (0.8-1.4) | 1.2 (0.9-1.6) | 1.2 (0.8-1.8) | 1.3 (0.7-2.4) |
| AOR (95% CI) | 1.0 (0.7-1.3) | 1.0 (0.7-1.3) | 1.0 (0.7-1.5) | 1.0 (0.5-1.9) |
| 17 | ||||
| Case/control | 61/71 | 69/70 | 31/35 | 18/14 |
| COR (95% CI) | 1.2 (0.8-1.7) | 1.3 (0.9-1.9) | 1.2 (0.7-2.0) | 1.7 (0.8-3.5) |
| AOR (95% CI) | 0.9 (0.6-1.3) | 1.0 (0.7-1.5) | 0.9 (0.5-1.5) | 1.3 (0.6-2.7) |
| 19 | ||||
| Case/control | 34/40 | 50/38 | 19/19 | 9/7 |
| COR (95% CI) | 1.1 (0.7-1.8) | 1.8 (1.1-2.7) | 1.3 (0.7-2.6) | 1.7 (0.6-4.7) |
| AOR (95% CI) | 0.8 (0.5-1.3) | 1.3 (0.8-2.0) | 1.0 (0.5-2.0) | 1.3 (0.5-3.6) |
Note: Referent group in the prior analysis was comprised of never exposed cases (n = 739) and controls (n = 1,085). The referent group in the current analysis was comprised of never exposed cases (n = 471) and controls (n = 645). Both adjusted analyses controlled for age at diagnosis or index year, vital status at interview, family history of breast cancer, personal history of breast cancer (before current diagnosis or index year), age at first live birth or stillbirth, occupational exposure to PCE, and study of origin.
Association between breast cancer and high cumulative PCE exposure: comparison of various cut points
| Latency period (years) | Prior Analysis >90th Percentile | Current Analysis >90th Percentile | Current Analysis Smoothing |
|---|---|---|---|
| 0 | |||
| RDD | 41.8 | 19.5 | 35 |
| Case/control | 18/21 | 56/64 | 26/32 |
| COR (95% CI) | 1.3 (0.7-2.4) | 1.2 (0.8-1.8) | 1.1 (0.7-1.9) |
| AOR (95% CI) | 1.3 (0.7-2.6) | 1.3 (0.9-1.9) | 1.3 (0.7-2.3) |
| 5 | |||
| RDD | 41.7 | 20.6 | 35 |
| Case/control | 17/16 | 53/55 | 24/30 |
| COR (95% CI) | 1.6 (0.8-3.1) | 1.3 (0.9-2.0) | 1.1 (0.6-1.9) |
| AOR (95% CI) | 1.5 (0.7-3.0) | 1.4 (0.9-2.1) | 1.3 (0.7-2.3) |
| 7 | |||
| RDD | 40.9 | 19.0 | 35 |
| Case/control | 17/13 | 51/49 | 23/25 |
| COR (95% CI) | 1.9 (0.9-4.0) | 1.5 (1.0-2.2) | 1.3 (0.7-2.3) |
| AOR (95% CI) | 1.7 (0.8-3.6) | 1.4 (0.9-2.2) | 1.4 (0.7-2.5) |
| 9 | |||
| RDD | 38.4 | 17.4 | 35 |
| Case/control | 16/11 | 47/43 | 21/19 |
| COR (95% CI) | 2.1 (1.0-4.6) | 1.5 (1.0-2.4) | 1.6 (0.8-3.0) |
| AOR (95% CI) | 1.9 (0.8-4.4) | 1.4 (0.9-2.2) | 1.6 (0.8-3.0) |
| 11 | |||
| RDD | 37.3 | 16.1 | 35 |
| Case/control | 12/8 | 40/37 | 17/14 |
| COR (95% CI) | 2.2 (0.9-5.4) | 1.5 (1.0-2.5) | 1.8 (0.8-3.6) |
| AOR (95% CI) | 1.8 (0.7-4.8) | 1.4 (0.9-2.4) | 1.8 (0.8-3.9) |
| 13 | |||
| RDD | 36.8 | 12.8 | 35 |
| Case/control | 8/5 | 37/32 | 13/10 |
| COR (95% CI) | 2.3 (0.8-7.2) | 1.7 (1.0-2.7) | 1.9 (0.8-4.6) |
| AOR (95% CI) | 1.7 (0.5-5.2) | 1.5 (0.9-2.5) | 2.0 (0.8-4.8) |
| 15 | |||
| RDD | 49.1 | 14.0 | 35 |
| Case/control | 2/3 | 20/22 | 8/5 |
| COR (95% CI) | 1.0 (0.2-5.9) | 1.3 (0.7-2.4) | 2.1 (0.7-6.6) |
| AOR (95% CI) | - | 1.0 (0.5-1.9) | 1.8 (0.6-5.6) |
| 17 | |||
| RDD | 40.6 | 11.4 | 35 |
| Case/control | 1/2 | 18/14 | 4/5 |
| COR (95% CI) | 0.7 (0.1-8.1) | 1.7 (0.8-3.5) | 1.1 (0.3-4.0) |
| AOR (95% CI) | - | 1.3 (0.6-2.7) | - |
| 19 | |||
| RDD | 169.9 | 9.5 | 35 |
| Case/control | 0/0 | 9/7 | 0/2 |
| COR (95% CI) | - | 1.7 (0.6-4.7) | - |
| AOR (95% CI) | - | 1.3 (0.5-3.6) | - |
Note: The referent group was comprised of never exposed cases (n = 471) and controls (n = 645). The adjusted analysis controlled for age at diagnosis or index year, vital status at interview, family history of breast cancer, personal history of breast cancer (before current diagnosis or index year), age at first live birth or stillbirth, occupational exposure to PCE, and study of origin.
Figure 1Comparison of Ln Measured PCE Concentration (ug/L) with Ln Model Estimated PCE Concentration (ug/L): Automated Method. This figure depicts the relationship between measured PCE concentration and model estimated PCE concentration using the automated method. There was a moderate level of correlation between measured and modeled PCE concentrations using the automated method (Spearman rank correlation coefficient (ρ = 0.65, p < 0.0001).
Figure 2Comparison of Ln Measured PCE Concentration (ug/L) with Ln Model Estimated PCE Concentration (ug/L): Manual Method. This figure depicts the relationship between measured PCE concentration and model estimated PCE concentration using the manual method. There was a moderate level of correlation between measured and modeled PCE concentrations using the manual method (ρ = 0.54, p < 0.001) but the magnitude of correlation was lower than that of the automated method.